Exploring the Potential Drug Target and Biomarker for COL1A2-AS1: Unveiling the Intrinsic Capabilities of this Protein

Target Name: COL1A2-AS1

NCBI ID: G101927525

Other Name(s): TCONS_00013888 | COL1A2 antisense RNA 1 | lncRNA8975-1

Exploring the Potential Drug Target and Biomarker for COL1A2-AS1: Unveiling the Intrinsic Capabilities of this Protein

The protein COL1A2-AS1 (Tcons00013888) has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various post-translational modifications (PTMs) have piqued the interest of researchers, and its functions continue to be unraveled. In this article, we will delve into the story of COL1A2-AS1, its structural features, and its potential as a drug target and biomarker.

Structure and Function

COL1A2-AS1, also known as Tcons00013888, is a 193-kDa protein that is expressed in various tissues, including epithelial, hematopoietic, and nervous cells. It is a member of the transforming growth factor beta (NF-kappa) signaling pathway, which is a well-established regulator of cell growth, differentiation, and survival. The protein plays a crucial role in the regulation of cell adhesion, migration, and the formation of tissues and organs during development.

COL1A2-AS1 has several unique features that make it an attractive drug target and biomarker. Its first and last exons are farnesylated, which is a well-established mark of protein stability and may influence its stability and interactions with other proteins. Additionally, COL1A2-AS1 has a unique N-terminal region that is rich in electrostatic potential and has been implicated in various cellular processes, including cell adhesion, migration, and the regulation of ion channels.

Expression and Localization

COL1A2-AS1 is highly expressed in various tissues, including the skin, gut, lung, and brain. Its expression is also known to be regulated by various factors, including Wnt, NF-kappa, andNotch. In addition, COL1A2-AS1 has been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer. This suggests that targeting this protein may be a promising strategy for the development of cancer therapies.

Post-Translational Modifications

COL1A2-AS1 has several post-translational modifications (PTMs), including phosphorylation, ubiquitination, and citrinization. These modifications have been implicated in various cellular processes, including cell adhesion, migration, and the regulation of ion channels. Additionally, COL1A2-AS1 has a unique HN-FY domain that is known to be involved in protein-protein interactions and may influence its stability and interactions with other proteins.

Drug Target Potential

The potential drug target for COL1A2-AS1 is its unique structure and various post-translational modifications. The protein's first and last exons are farnesylated, which may influence its stability and interactions with other proteins. Additionally, the N-terminal region of COL1A2-AS1 is rich in electrostatic potential and has been implicated in various cellular processes.

Biomarker Potential

COL1A2-AS1 has been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer. This suggests that targeting this protein may be a promising strategy for the development of cancer therapies. Additionally, the protein's unique structure and various post-translational modifications make it an attractive biomarker for various diseases.

Conclusion

In conclusion, COL1A2-AS1 is a unique protein with various features that make it an attractive drug target and biomarker. Its first and last exons being farnesylated, rich N-terminal region, and unique structure are likely to be the basis for its potential as a drug target. Further research is needed to fully understand the functions of COL1A2-AS1 and its potential as a drug

Protein Name: COL1A2 Antisense RNA 1

More Common Targets